27320055|t|Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells
27320055|a|Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. In addition to methamphetamine (METH), these drugs include 3,4-methylenedioxy-methamphetamine (MDMA) and commercial preparations of synthetic cathinones including 3,4-methylenedioxypyrovalerone (MDPV), typically referred to as " bath salts ." These psychostimulants exert neurotoxic effects by altering monoamine systems in the brain. Additionally, METH and MDMA adversely affect the integrity of the blood-brain barrier (BBB): there are no current reports on the effects of MDPV on the BBB. The aim of this study was to compare the effects of METH, MDMA and MDPV on bovine brain microvessel endothelial cells (bBMVECs), an accepted in vitro model of the BBB. Confluent bBMVEC monolayers were treated with METH, MDMA and MDPV (0.5mM-2.5mM) for 24h. METH and MDMA increased lactate dehydrogenase release only at the highest concentration (2.5mM), whereas MDPV induced cytotoxicity at all concentration s. MDMA and METH decreased cellular proliferation only at 2.5mM, with similar effects observed after MDPV exposures starting at 1mM. Only MDPV increased reactive oxygen species production at all concentrations tested whereas all 3 drugs increased nitric oxide production. Morphological analysis revealed different patterns of compound - induced cell damage. METH induced vacuole formatio n at 1mM and disruption of the monolayer at 2.5mM. MDMA induced disruption of the endothelial monolayer from 1mM without vacuolization. On the other hand, MDPV induced monolayer disruption at doses â‰¥0.5mM without vacuole formation; at 2.5mM, the few remaining cells lacked endothelial morphology. These data suggest that even though these synthetic psychostimulants alter monoaminergic systems, they each induce BBB toxicity by different mechanisms with MDPV being the most toxic.
27320055	0	15	Methamphetamine	T103	UMLS:C0025611
27320055	17	50	3,4-methylenedioxymethamphetamine	T103	UMLS:C0115471
27320055	52	56	MDMA	T103	UMLS:C0115471
27320055	62	92	3,4-methylenedioxypyrovalerone	T103	UMLS:C2974592
27320055	94	98	MDPV	T103	UMLS:C2974592
27320055	120	137	cytotoxic effects	T038	UMLS:C0596402
27320055	141	147	bovine	T204	UMLS:C0007452
27320055	148	153	brain	T017	UMLS:C0006104
27320055	154	165	microvessel	T017	UMLS:C2350570
27320055	166	183	endothelial cells	T017	UMLS:C0225336
27320055	184	198	Designer drugs	T103	UMLS:C0011684
27320055	207	233	synthetic psychostimulants	T103	UMLS:C0304403
27320055	264	271	problem	T033	UMLS:C0033213
27320055	275	285	drug abuse	T038	UMLS:C0013146
27320055	290	299	addiction	T038	UMLS:C1510472
27320055	316	331	methamphetamine	T103	UMLS:C0025611
27320055	333	337	METH	T103	UMLS:C0025611
27320055	346	351	drugs	T103	UMLS:C0011684
27320055	360	394	3,4-methylenedioxy-methamphetamine	T103	UMLS:C0115471
27320055	396	400	MDMA	T103	UMLS:C0115471
27320055	406	416	commercial	T170	UMLS:C0680536
27320055	433	453	synthetic cathinones	T103	UMLS:C0054876
27320055	464	494	3,4-methylenedioxypyrovalerone	T103	UMLS:C2974592
27320055	496	500	MDPV	T103	UMLS:C2974592
27320055	530	540	bath salts	T103	UMLS:C0771243
27320055	550	566	psychostimulants	T103	UMLS:C0304403
27320055	573	591	neurotoxic effects	T037	UMLS:C0235032
27320055	629	634	brain	T017	UMLS:C0006104
27320055	650	654	METH	T103	UMLS:C0025611
27320055	659	663	MDMA	T103	UMLS:C0115471
27320055	664	680	adversely affect	T038	UMLS:C0879626
27320055	702	721	blood-brain barrier	T017	UMLS:C0005854
27320055	723	726	BBB	T017	UMLS:C0005854
27320055	750	757	reports	T170	UMLS:C0684224
27320055	776	780	MDPV	T103	UMLS:C2974592
27320055	788	791	BBB	T017	UMLS:C0005854
27320055	809	814	study	T062	UMLS:C2603343
27320055	845	849	METH	T103	UMLS:C0025611
27320055	851	855	MDMA	T103	UMLS:C0115471
27320055	860	864	MDPV	T103	UMLS:C2974592
27320055	868	874	bovine	T204	UMLS:C0007452
27320055	875	880	brain	T017	UMLS:C0006104
27320055	881	892	microvessel	T017	UMLS:C2350570
27320055	893	910	endothelial cells	T017	UMLS:C0225336
27320055	912	919	bBMVECs	T017	UMLS:C0225336
27320055	934	948	in vitro model	T062	UMLS:C1515654
27320055	956	959	BBB	T017	UMLS:C0005854
27320055	971	977	bBMVEC	T017	UMLS:C0225336
27320055	978	988	monolayers	T017	UMLS:C0934502
27320055	1007	1011	METH	T103	UMLS:C0025611
27320055	1013	1017	MDMA	T103	UMLS:C0115471
27320055	1022	1026	MDPV	T103	UMLS:C2974592
27320055	1050	1054	METH	T103	UMLS:C0025611
27320055	1059	1063	MDMA	T103	UMLS:C0115471
27320055	1074	1095	lactate dehydrogenase	T103	UMLS:C0022917
27320055	1155	1159	MDPV	T103	UMLS:C2974592
27320055	1168	1180	cytotoxicity	T038	UMLS:C0596402
27320055	1205	1209	MDMA	T103	UMLS:C0115471
27320055	1214	1218	METH	T103	UMLS:C0025611
27320055	1229	1251	cellular proliferation	T038	UMLS:C0596290
27320055	1303	1307	MDPV	T103	UMLS:C2974592
27320055	1340	1344	MDPV	T103	UMLS:C2974592
27320055	1355	1378	reactive oxygen species	T103	UMLS:C0162772
27320055	1433	1438	drugs	T103	UMLS:C0011684
27320055	1449	1461	nitric oxide	T103	UMLS:C0028128
27320055	1474	1496	Morphological analysis	T062	UMLS:C0936012
27320055	1528	1536	compound	T103	UMLS:C1706082
27320055	1560	1564	METH	T103	UMLS:C0025611
27320055	1573	1580	vacuole	T017	UMLS:C0042219
27320055	1621	1630	monolayer	T017	UMLS:C0934502
27320055	1641	1645	MDMA	T103	UMLS:C0115471
27320055	1672	1683	endothelial	T017	UMLS:C0225336
27320055	1684	1693	monolayer	T017	UMLS:C0934502
27320055	1711	1724	vacuolization	T033	UMLS:C0010840
27320055	1745	1749	MDPV	T103	UMLS:C2974592
27320055	1758	1767	monolayer	T017	UMLS:C0934502
27320055	1803	1810	vacuole	T017	UMLS:C0042219
27320055	1850	1855	cells	T017	UMLS:C0007634
27320055	1929	1955	synthetic psychostimulants	T103	UMLS:C0304403
27320055	2002	2005	BBB	T017	UMLS:C0005854
27320055	2006	2014	toxicity	T037	UMLS:C0013221
27320055	2044	2048	MDPV	T103	UMLS:C2974592